Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026
Benzinga Newsdesk 7 hours ago
News
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief Scientific Officer,
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief Scientific Officer, Dr. Gary Barnette, will deliver a podium presentation at ObesityWeek 2026, taking place November 14-17, 2026, in Washington DC. Results will be presented from a post hoc analysis of physical function in patients ≥65 years with obesity receiving a GLP-1 RA from the positive Phase 2b QUALITY study.